User contributions for Muhammad Waleed
Jump to navigation
Jump to search
5 September 2024
- 01:5101:51, 5 September 2024 diff hist +1,921 m GAPO syndrome No edit summary current Tag: Visual edit
18 July 2024
- 09:2209:22, 18 July 2024 diff hist +12,217 Acute Fibrinous and Organizing Pneumonia No edit summary current Tag: Visual edit: Switched
- 08:5108:51, 18 July 2024 diff hist +2,017 N Acute Fibrinous and Organizing Pneumonia Created page with "__NOTOC__ {{xyz}} '''To view the main page click here.''' {{CMG}}; {{AE}} Person 1, Person 2, Your Name ==Overview== ==Historical Perspective== ==Classification== ==Pathophysiology== ==Causes== ==Type page name here differential diagnosis|Dif..."
23 May 2024
- 14:5114:51, 23 May 2024 diff hist +6,189 Glofitamab-gxbm No edit summary current
- 14:4014:40, 23 May 2024 diff hist +2,614 N Glofitamab-gxbm Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft..."
- 14:2214:22, 23 May 2024 diff hist +5,524 Rozanolixizumab-noli No edit summary current
- 12:4312:43, 23 May 2024 diff hist +3,235 N Rozanolixizumab-noli Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac..."
16 May 2024
- 10:1510:15, 16 May 2024 diff hist +132 Avacincaptad pegol No edit summary current
- 10:1410:14, 16 May 2024 diff hist +505 Talquetamab-tgvs No edit summary current
- 10:1110:11, 16 May 2024 diff hist +3,255 N Avacincaptad pegol Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV..."
- 09:3109:31, 16 May 2024 diff hist +25 N File:Talvey (talquetamab-tgvs).png image for the drug Talvey current
- 09:2809:28, 16 May 2024 diff hist +1,807 Talquetamab-tgvs No edit summary
13 May 2024
- 20:3820:38, 13 May 2024 diff hist +2,766 N Talquetamab-tgvs Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent..."
16 January 2024
- 20:1220:12, 16 January 2024 diff hist −1,769 m Triple M Syndrome No edit summary current Tag: Visual edit
27 September 2023
- 09:4309:43, 27 September 2023 diff hist +65 GAPO syndrome →Overview Tag: Visual edit
8 September 2023
- 21:3021:30, 8 September 2023 diff hist +1 m GAPO syndrome No edit summary Tag: Visual edit
- 21:2821:28, 8 September 2023 diff hist +122 Microbiome No edit summary current Tag: Visual edit
- 21:0421:04, 8 September 2023 diff hist +22 GAPO syndrome No edit summary
- 21:0321:03, 8 September 2023 diff hist +13 GAPO syndrome No edit summary
- 21:0221:02, 8 September 2023 diff hist +86 GAPO syndrome No edit summary Tag: Visual edit: Switched
31 August 2023
- 15:3015:30, 31 August 2023 diff hist +3,918 GAPO syndrome No edit summary Tag: Visual edit
- 15:2515:25, 31 August 2023 diff hist +1,417 Triple M Syndrome →Classification Tag: Visual edit
10 August 2023
- 04:2204:22, 10 August 2023 diff hist +496 Triple M Syndrome No edit summary Tag: Visual edit
- 04:1904:19, 10 August 2023 diff hist +314 Triple M Syndrome →Historical Perspective Tag: Visual edit
- 04:0504:05, 10 August 2023 diff hist +246 m Triple M Syndrome No edit summary Tag: Visual edit: Switched
- 03:5403:54, 10 August 2023 diff hist +5,250 N Triple M Syndrome Created page with "__NOTOC__ {{SI}} '''For patient information, click Insert page name here''' {{CMG}} {{SK}} == Overview == ==Historical Perspective== ==Classification== == Pathophysiology== === Genetics === === Associated Conditions=== ===Gross Pathology=== ===Microscopic Pathology=== ==Causes== ===Life Threatening Causes=== Life-threatening causes include conditions which may result in death or permanent disability within 24 ho..."
- 03:2903:29, 10 August 2023 diff hist +84 N Template:MWA Created page with "Muhammad Waleed, M.B.B.S.[mailto:muhammad_waleed@ymail.com]" current
8 August 2023
- 19:1319:13, 8 August 2023 diff hist +3,557 Microbiome →Metabolic Syndrome Tag: Visual edit
1 August 2023
- 17:5517:55, 1 August 2023 diff hist +667 Microbiome →Type 2 diabetes mellitus complications Tag: Visual edit
16 July 2023
- 19:4319:43, 16 July 2023 diff hist +1,945 Microbiome →Irritable Bowel Syndrome (IBS) Tag: Visual edit
- 18:3418:34, 16 July 2023 diff hist −91 Microbiome →Irritable Bowel Syndrome (IBS) Tag: Visual edit
- 18:2818:28, 16 July 2023 diff hist +624 Microbiome →Effects on pathogenesis of various diseases Tag: Visual edit
6 July 2023
- 16:5216:52, 6 July 2023 diff hist +1,448 Microbiome →Effects on cognition Tag: Visual edit